Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sigyn TherapeuticsSIGY Debt-to-Equity is -0.48 as of Sep. 2025. The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Sigyn Therapeutics ranks worse than 104275.18% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sigyn Therapeutics's Debt-to-Equity or its related term are showing as below:
SIGY'
s Debt-to-Equity Range Over the Past 10 Years
Min: -7.23 Med: -0.66 Max: 5.24
Current: -0.48
During the past 11 years, the highest Debt-to-Equity Ratio of Sigyn Therapeutics was 5.24. The lowest was -7.23. And the median was -0.66.
SIGY's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15
vs SIGY: -0.48
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sigyn Therapeutics Debt-to-Equity Related Terms
Sigyn Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sigyn Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SIGY vs CNBX, LIPO, CARM: Debt-to-Equity Comparison
For the Biotechnology subindustry, Sigyn Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sigyn Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sigyn Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sigyn Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sigyn Therapeutics (SIGY) has a Debt-to-Equity of -0.48 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sigyn Therapeutics and its competitors. According to the industry distribution chart, Sigyn Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Sigyn Therapeutics' Debt-to-Equity too high?
Sigyn Therapeutics' current Debt-to-Equity is -0.48. Based on the distribution chart, Sigyn Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Sigyn Therapeutics' Debt-to-Equity compare to CNBX and LIPO?
According to the Biotechnology industry distribution chart, Sigyn Therapeutics ranks #999999 out of 959 companies for Debt-to-Equity. This places Sigyn Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sigyn Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sigyn Therapeutics's current Debt-to-Equity is -0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigyn Therapeutics stock overvalued right now?
Sigyn Therapeutics (SIGY) has a current Debt-to-Equity of -0.48. The current Debt-to-Equity is -0.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sigyn Therapeutics (SIGY), the current Debt-to-Equity is -0.48 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SIGY has been successfully added to your 
